Abstract Background Abnormalities in inflammation resolution function are closely associated with chronic inflammation, and proresolution therapies may provide new opportunities for the treatment of inflammatory bowel disease (IBD). Developmental endothelial locus 1 (DEL-1) is an important endogenous molecule that regulates tissue immune homeostasis and promotes resolution of inflammation, but its effect on IBD remains unknown. Here, we aimed to explore the expression and roles of DEL-1 in IBD. Methods DEL-1 levels were examined in patients with IBD, mice with colitis, and LPS-induced RAW264.7 cells. DEL-1 overexpression plasmids and/or DEL-1-Fc intervened in cells and mice to explore it effects in the acute and recovery phases of inflammation. Moreover, flow cytometry, RNA-Seq, chromatin immunoprecipitation (ChIP), dual-luciferase reporter assays and 16S rRNA were used to illustrate the potential mechanism of DEL-1 in colitis. Results DEL-1 levels were remarkably lower in IBD patients, colitis mice, and LPS-induced RAW264.7 cells, while the levels increased with inflammation to resolve. Transfection with DEL-1 overexpression plasmid and/or DEL-1-Fc intervention reduces levels of inflammatory cytokines in both phases and upregulates reparative gene levels in the recovery phase. Mechanistically, we demonstrated that DEL-1 inhibits Cytosine monophosphate kinase 2 (Cmpk2)-dependent mtDNA synthesis, thereby inhibiting the cGAS-STING pathway to ameliorate intestinal inflammation. Moreover, DEL-1 promoted reparative macrophage transition in the repair model of colitis. Spi1 was identified as a transcription factor that regulates Cmpk2 and the reparative gene Il10. Intervention with overexpression plasmid of Spi1 or Cmpk2 or the STING agonist DMXAA reverses the effects of DEL-1. DEL-1 also inhibits neutrophil recruitment, repairs the intestinal barrier, and improves intestinal microbiota dysbiosis. Conclusion This is the first study to show that DEL-1 effectively attenuates colonic inflammation in mice with DSS-induced colitis by inhibits the Cmpk2-cGAS-STING pathway and regulates reparatory macrophage transition, thus providing a novel therapeutic target for IBD.
Read full abstract